Shares of Corbus Pharmaceuticals Holdings Inc. CRBP slipped 5.31% to $14.28 Monday, on what proved to be an all-around mixed ...

Corbus Pharmaceuticals Holdings Inc. closed $46.82 short of its 52-week high ($61.90), which the company achieved on July ...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating on December 2.Pick the best ...

In a report released yesterday, Graig Suvannavejh from Mizuho Securities downgraded Alector (ALEC – Research Report) to a Hold, with a price ...

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD ...

Piper Sandler started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research note released on ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a ...

NORWOOD, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors.

Corbus Pharmaceuticals has successfully reinvented itself with a portfolio of assets targeting validated approaches in drug development. The company's pipeline includes three main candidates: CRB-701, ...

NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...